Letter Submitted: Draft NCD for Monoclonal Antibodies Directed Against Amyloid for the treatment of Alzheimer’s Disease
We have serious concerns about CMS’s draft national coverage determination (NCD) – issued January 11, 2022 – to limit Medicare coverage for monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s Disease (AD) to patients enrolled in...Read more